February 28, 2014
The National Center of Neurology and Psychiatry (NCNP) announced on February 24 that it will begin an investigator-initiated trial of an analog of the glycolipid alpha-galactosylceramide (development code: OCH) for the treatment of multiple sclerosis (MS) in early March. The...read more